| AMEFX | FASGX | AMEFX / FASGX | |
| Total Expense Ratio | 0.37 | 0.63 | 59% |
| Annual Report Gross Expense Ratio | 0.37 | 0.66 | 56% |
| Fund Existence | 17 years | 34 years | - |
| Gain YTD | 9.676 | 18.821 | 51% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 140B | 7.71B | 1,816% |
| Annual Yield % from dividends | 3.69 | 1.58 | 233% |
| Returns for 1 year | 8.96 | 14.06 | 64% |
| Returns for 3 years | 28.15 | 42.65 | 66% |
| Returns for 5 years | 29.21 | 33.11 | 88% |
| Returns for 10 years | 54.50 | 90.24 | 60% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MCYSX | 13.09 | 0.07 | +0.54% |
| NYLI Candriam Emerging Markets Eq Cl R6 | |||
| GSRRX | 10.67 | 0.05 | +0.47% |
| Goldman Sachs Rising Dividend Gr R | |||
| GSPQX | 18.30 | 0.05 | +0.27% |
| Goldman Sachs US Eq Div and Premium C | |||
| TRBCX | 213.17 | 0.44 | +0.21% |
| T. Rowe Price Blue Chip Growth | |||
| NRIFX | 22.56 | 0.03 | +0.13% |
| Nuveen Real Asset Income R6 | |||